Sylvant
| Chemical Name | siltuximab |
| Dosage Form | Injection (intravenous; 100 mg, 400 mg) |
| Drug Class | Receptor antagonists |
| System | Blood |
| Company | EUSA Pharma |
| Approval Year | 2014 |
Indication
- For the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.